NKTR•benzinga•
Nektar Therapeutics Completes Target Enrollment In REZOLVE-AD Phase 2B Study Of Rezpegaldesleukin In Patients With Atopic Dermatitis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga